Based on the criteria of The European Group for the Immunological Classification of Leukemias (EGIL) [20], primary immunophenotypic studies identified BI-ALL in five patients (pts #1, #2, #3, #4, and #6) and BIII-ALL in one patient (pt #5). Here, CACNA1A is linked to acute lymphoblastic leukemia.